GLP-1 Oracle
Providers Coverage Costs Reference
Compare providers

51/51 states verified · 25/25 providers audited

Cost

Ozempic and Mounjaro are two molecules with the same label

Ozempic and Mounjaro are different molecules from different companies, and they carry the same FDA label. Ozempic is semaglutide, made by Novo Nordisk.

What that is based on

Mounjaro is tirzepatide, made by Eli Lilly. Both are approved to improve blood sugar in type 2 diabetes, and both carry a cardiovascular indication in that population. Neither is approved for weight management: those are Wegovy and Zepbound, the same two molecules under different labels. Paying cash, Lilly sells Mounjaro through LillyDirect at $499 a month and charges the same at every one of its six doses. Novo Nordisk sells Ozempic through NovoCare Pharmacy at $149 a month at 1.5 mg and $199 a month for the 0.25 mg and 0.5 mg pens if you are new to the offer, stepping up to $349 and $499 from 31 December 2026. Ozempic's list price is $1,027.51 a package and almost nobody pays it. On coverage the two are treated as one class rather than as rivals: across the 51 US Medicaid jurisdictions this site has read, semaglutide is covered subject to prior authorization in 13 and tirzepatide in 11, and the conditions attached are about the diagnosis rather than the brand.

By John Weeks Updated September 12, 2026

Cash price · per month

$149 to $499

Self-pay, direct from each manufacturer. Two of the Ozempic prices step up on 31 December 2026.

What it costs at each dose

What Ozempic and Mounjaro are two molecules with the same label costs at each dose, with the caveat on each figure.
Brand and dose Per month Note
Mounjaro, every dose $499 2.5 through 15 mg all carry the same self-pay price
Ozempic, 1.5 mg $149 Novo defines a month at this dose as 1 bottle of 30 tablets
Ozempic, 0.25 mg and 0.5 mg $199 First 2 months, and only if you are new to the offer
Ozempic, 0.25, 0.5 or 1 mg $349 After the first 2 fills, from 31 December 2026
Ozempic, 2 mg $499 After the first 2 fills, from 31 December 2026
  • Mounjaro, every dose $499

    2.5 through 15 mg all carry the same self-pay price

  • Ozempic, 1.5 mg $149

    Novo defines a month at this dose as 1 bottle of 30 tablets

  • Ozempic, 0.25 mg and 0.5 mg $199

    First 2 months, and only if you are new to the offer

  • Ozempic, 0.25, 0.5 or 1 mg $349

    After the first 2 fills, from 31 December 2026

  • Ozempic, 2 mg $499

    After the first 2 fills, from 31 December 2026

Self-pay prices read from Eli Lilly and Novo Nordisk's own pages on 12 September 2026. Mounjaro's figure is a "starting at" price and carries Lilly's note that additional taxes and fees may apply. Ozempic's list price is $1,027.51 a package against every dose line, and it sits on a separate page reached from a "List price explained" link. A month is not one unit across these rows: Novo defines it as 1 bottle of 30 tablets for the tablet and 1 box of 1 pen for the injection, and Lilly prices a single-dose prefilled pen.

The short version

The molecules
Semaglutide in Ozempic, from Novo Nordisk. Tirzepatide in Mounjaro, from Eli Lilly. Two different molecules, unlike Wegovy and Ozempic
The label they share
Both are approved to improve blood sugar in type 2 diabetes. Neither is approved for weight management
Cardiovascular indication
Lilly states Mounjaro also reduces the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them
Mounjaro, self-pay
$499 a month at every dose from 2.5 through 15 mg
The same molecule, other label
Zepbound is tirzepatide too, from the same company through the same channel, and it runs $299 at 2.5 mg and $699 at 10 mg against Mounjaro's flat $499. So the diabetes label is dearer at the starting dose and cheaper at the higher ones
Ozempic list price
$1,027.51 per package, every dose and both forms
New York Medicaid
Excludes GLP-1 agonists, naming Ozempic and Mounjaro among others, where the indication is weight loss
Nebraska Medicaid
Preferred agents require a type 2 diabetes diagnosis and a trial and failure of metformin, or ASCVD with type 2 diabetes
Oklahoma SoonerCare
GIP/GLP-1 agonists require an FDA-approved diagnosis of type 2 diabetes mellitus
What Medicaid does across all 51
Semaglutide is covered subject to prior authorization in 13 of 51 jurisdictions and refused in 12. Tirzepatide is covered in 11 and refused in 11
What this page does not do
It does not say which one works better or which one to ask for. That is a question for a prescriber, and the answer depends on a diagnosis we cannot see

Referral fee from some of these. It never changes what you pay. How we make money

Providers offering this medication

More on Semaglutide

Sources

Every claim above is checked against the primary text, and the date is the day we last opened it.

8 cited records
  1. 1
    Authentic Mounjaro (tirzepatide) Shipped to You | LillyDirect

    Eli Lilly and Company Primary text read and checked Checked September 12, 2026

  2. 2
    Authentic Zepbound (tirzepatide) Shipped to You | LillyDirect

    Eli Lilly and Company Primary text read and checked Checked September 3, 2026

  3. 3
    Ozempic list price and insurance coverage explained

    Novo Nordisk (NovoCare) Primary text read and checked Checked September 12, 2026

  4. 4
    Ozempic savings offer

    Novo Nordisk (NovoCare) Primary text read and checked Checked September 12, 2026

  5. 5
    NYRx Drug Class Coverage Overview: GLP-1 Receptor Agonists, Type 2 Diabetes

    NYRx, the New York State Medicaid Pharmacy Program Primary text read and checked Checked August 25, 2026

  6. 6
    Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria, August 3, 2026

    Nebraska Department of Health and Human Services Primary text read and checked Checked August 26, 2026

  7. 7
    SoonerCare Prior Authorization 2026: Endocrine and Diabetic Agents

    Oklahoma Health Care Authority (OHCA) Primary text read and checked Checked August 28, 2026

  8. 8
    Kentucky Medicaid Prior Authorization Criteria, Version: August 2026

    Kentucky Cabinet for Health and Family Services, Department for Medicaid Services (MedImpact Kentucky Medicaid portal) Primary text read and checked Checked August 27, 2026